-
1
-
-
84907198355
-
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
-
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959-66.
-
(2014)
J Clin Oncol
, vol.32
, pp. 2959-2966
-
-
Adams, S.1
Gray, R.J.2
Demaria, S.3
Goldstein, L.4
Perez, E.A.5
Shulman, L.N.6
-
2
-
-
84896872171
-
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
-
Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-8.
-
(2014)
Ann Oncol
, vol.25
, pp. 611-618
-
-
Dieci, M.V.1
Criscitiello, C.2
Goubar, A.3
Viale, G.4
Conte, P.5
Guarneri, V.6
-
3
-
-
84905178989
-
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
-
Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25:1544-50.
-
(2014)
Ann Oncol
, vol.25
, pp. 1544-1550
-
-
Loi, S.1
Michiels, S.2
Salgado, R.3
Sirtaine, N.4
Jose, V.5
Fumagalli, D.6
-
4
-
-
84875722651
-
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
-
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860-7.
-
(2013)
J Clin Oncol
, vol.31
, pp. 860-867
-
-
Loi, S.1
Sirtaine, N.2
Piette, F.3
Salgado, R.4
Viale, G.5
Eenoo, F.6
-
5
-
-
84927138902
-
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
-
Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983-91.
-
(2015)
J Clin Oncol
, vol.33
, pp. 983-991
-
-
Denkert, C.1
Minckwitz, G.2
Brase, J.C.3
Sinn, B.V.4
Gade, S.5
Kronenwett, R.6
-
6
-
-
84969268378
-
Association of stromal tumor infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer
-
Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, et al. Association of stromal tumor infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2015;15:1-9.
-
(2015)
JAMA Oncol
, vol.15
, pp. 1-9
-
-
Perez, E.A.1
Ballman, K.V.2
Tenner, K.S.3
Thompson, E.A.4
Badve, S.S.5
Bailey, H.6
-
7
-
-
84871921577
-
Immunologic privilege in the central nervous system and the blood-brain barrier
-
Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, Doolittle ND, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:13-21.
-
(2013)
J Cereb Blood Flow Metab
, vol.33
, pp. 13-21
-
-
Muldoon, L.L.1
Alvarez, J.I.2
Begley, D.J.3
Boado, R.J.4
Zoppo, G.J.5
Doolittle, N.D.6
-
8
-
-
26244449275
-
Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells
-
Hudson LC, Bragg DC, Tompkins MB, Meeker RB. Astrocytes and microglia differentially regulate trafficking of lymphocyte subsets across brain endothelial cells. Brain Res. 2005;1058:148-60.
-
(2005)
Brain Res
, vol.1058
, pp. 148-160
-
-
Hudson, L.C.1
Bragg, D.C.2
Tompkins, M.B.3
Meeker, R.B.4
-
9
-
-
53949093698
-
Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization
-
Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008;25:799-810.
-
(2008)
Clin Exp Metastasis
, vol.25
, pp. 799-810
-
-
Fitzgerald, D.P.1
Palmieri, D.2
Hua, E.3
Hargrave, E.4
Herring, J.M.5
Qian, Y.6
-
10
-
-
77956855574
-
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels
-
Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12:748-54.
-
(2010)
Neoplasia
, vol.12
, pp. 748-754
-
-
Lin, Q.1
Balasubramanian, K.2
Fan, D.3
Kim, S.J.4
Guo, L.5
Wang, H.6
-
11
-
-
35349024802
-
CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system
-
Müller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol. 2007;179:2774-86.
-
(2007)
J Immunol
, vol.179
, pp. 2774-2786
-
-
Müller, M.1
Carter, S.L.2
Hofer, M.J.3
Manders, P.4
Getts, D.R.5
Getts, M.T.6
-
12
-
-
77951837763
-
Trafficking of immune cells in the central nervous system
-
Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368-79.
-
(2010)
J Clin Invest
, vol.120
, pp. 1368-1379
-
-
Wilson, E.H.1
Weninger, W.2
Hunter, C.A.3
-
14
-
-
84939633426
-
B7-h4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity
-
Rahbar R, Lin A, Ghazarian M, Yau HL, Paramathas S, Lang PA, et al. B7-h4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. Cancer Immunol Res. 2015;3:184-95.
-
(2015)
Cancer Immunol Res
, vol.3
, pp. 184-195
-
-
Rahbar, R.1
Lin, A.2
Ghazarian, M.3
Yau, H.L.4
Paramathas, S.5
Lang, P.A.6
-
15
-
-
84919385463
-
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type
-
Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23:2965-70.
-
(2014)
Cancer Epidemiol Biomarkers Prev
, vol.23
, pp. 2965-2970
-
-
Gatalica, Z.1
Snyder, C.2
Maney, T.3
Ghazalpour, A.4
Holterman, D.A.5
Xiao, N.6
-
16
-
-
84891654921
-
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
-
Berghoff AS, Ricken G, Widhalm G, Rajky O, Hainfellner JA, Birner P, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2014;33:42-9.
-
(2014)
Clin Neuropathol
, vol.33
, pp. 42-49
-
-
Berghoff, A.S.1
Ricken, G.2
Widhalm, G.3
Rajky, O.4
Hainfellner, J.A.5
Birner, P.6
-
17
-
-
84925266488
-
Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases
-
Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2015;66:289-99.
-
(2015)
Histopathology
, vol.66
, pp. 289-299
-
-
Berghoff, A.S.1
Ricken, G.2
Widhalm, G.3
Rajky, O.4
Dieckmann, K.5
Birner, P.6
-
18
-
-
84943241524
-
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
-
Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;8:1064-75.
-
(2015)
Neuro Oncol
, vol.8
, pp. 1064-1075
-
-
Berghoff, A.S.1
Kiesel, B.2
Widhalm, G.3
Rajky, O.4
Ricken, G.5
Wöhrer, A.6
-
19
-
-
84950980021
-
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
-
Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6:40836-49.
-
(2015)
Oncotarget
, vol.6
, pp. 40836-40849
-
-
Harter, P.N.1
Bernatz, S.2
Scholz, A.3
Zeiner, P.S.4
Zinke, J.5
Kiyose, M.6
-
20
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
21
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
127ra37
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
-
(2012)
Sci Transl Med
, vol.4
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
-
22
-
-
4243096258
-
B7-H1 expression on non small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
-
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Aita H, Nishimura M. B7-H1 expression on non small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-100.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5094-5100
-
-
Konishi, J.1
Yamazaki, K.2
Azuma, M.3
Kinoshita, I.4
Dosaka-Aita, H.5
Nishimura, M.6
-
24
-
-
84902582266
-
PD-L1 expression in triple-negative breast cancer
-
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361-70.
-
(2014)
Cancer Immunol Res
, vol.2
, pp. 361-370
-
-
Mittendorf, E.A.1
Philips, A.V.2
Meric-Bernstam, F.3
Qiao, N.4
Wu, Y.5
Harrington, S.6
-
25
-
-
84901620362
-
T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands
-
Karasar P, Esendagli G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat. 2014;145:605-14.
-
(2014)
Breast Cancer Res Treat
, vol.145
, pp. 605-614
-
-
Karasar, P.1
Esendagli, G.2
-
26
-
-
84928773222
-
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
-
Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501-9.
-
(2015)
Br J Cancer
, vol.112
, pp. 1501-1509
-
-
Abiko, K.1
Matsumura, N.2
Hamanishi, J.3
Horikawa, N.4
Murakami, R.5
Yamaguchi, K.6
-
27
-
-
84959904342
-
Reflections on immune checkpoint inhibition in non-small cell lung cancer
-
Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res. 2014;3:411-3.
-
(2014)
Transl Lung Cancer Res
, vol.3
, pp. 411-413
-
-
Leventakos, K.1
Mansfield, A.S.2
-
28
-
-
84954429886
-
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
-
Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. OncoImmunology. 2016. doi:10.1080/2162402X.2015.1057388
-
(2016)
OncoImmunology
-
-
Berghoff, AS.1
Fuchs, E.2
Ricken, G.3
Mlecnik B.Bindea, G.4
Spanberger, T.5
-
29
-
-
77955018897
-
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
-
Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nunès JA, et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol. 2010;22:651-60.
-
(2010)
Int Immunol
, vol.22
, pp. 651-660
-
-
Ghiotto, M.1
Gauthier, L.2
Serriari, N.3
Pastor, S.4
Truneh, A.5
Nunès, J.A.6
-
30
-
-
84936749833
-
Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
-
Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-12.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2004-2012
-
-
Gettinger, S.N.1
Horn, L.2
Gandhi, L.3
Spigel, D.R.4
Antonia, S.J.5
Rizvi, N.A.6
-
31
-
-
77957664158
-
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non small cell lung cancer
-
Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non small cell lung cancer. Cell Mollmmunol. 2010;7:389-95.
-
(2010)
Cell Mollmmunol
, vol.7
, pp. 389-395
-
-
Zhang, Y.1
Huang, S.2
Gong, D.3
Qin, Y.4
Shen, Q.5
-
32
-
-
0026700235
-
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
-
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887-95.
-
(1992)
EMBO J
, vol.11
, pp. 3887-3895
-
-
Ishida, Y.1
Agata, Y.2
Shibahara, K.3
Honjo, T.4
-
33
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
34
-
-
10344220548
-
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
-
Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 17174-17179
-
-
Thompson, R.H.1
Gillett, M.D.2
Cheville, J.C.3
Lohse, C.M.4
Dong, H.5
Webster, W.S.6
-
35
-
-
84896488675
-
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients
-
Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63:395-406.
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 395-406
-
-
Sun, S.1
Fei, X.2
Mao, Y.3
Wang, X.4
Garfield, D.H.5
Huang, O.6
-
36
-
-
84920956735
-
Predictive correlates of response to the anti-PD L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
Fine, G.D.4
Hamid, O.5
Gordon, M.S.6
-
37
-
-
84965058325
-
Modes of immune response
-
Male D, Brostoff J, Roth D, Roitt I, editors. Immunology
-
Male D. Modes of immune response. In: Male D, Brostoff J, Roth D, Roitt I, editors. Immunology. Elselvier Ltd; 2006. p. 127-249.
-
(2006)
Elselvier Ltd
, pp. 127-249
-
-
Male, D.1
-
38
-
-
84895779425
-
PD-L1 expression is increased in a subset of basal type breast cancer cells
-
Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557.
-
(2014)
PLoS One
, vol.9
-
-
Soliman, H.1
Khalil, F.2
Antonia, S.3
-
39
-
-
84891534246
-
Programmed death ligand-1 expression in non-small cell lung cancer
-
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-16.
-
(2014)
Lab Invest
, vol.94
, pp. 107-116
-
-
Velcheti, V.1
Schalper, K.A.2
Carvajal, D.E.3
Anagnostou, V.K.4
Syrigos, K.N.5
Sznol, M.6
-
40
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
-
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84-8.
-
(2007)
Nat Med
, vol.13
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
Crane, C.A.4
Parney, I.F.5
Barry, J.J.6
-
41
-
-
84890020587
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
-
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355-63.
-
(2013)
Cancer Discov
, vol.3
, pp. 1355-1363
-
-
Akbay, E.A.1
Koyama, S.2
Carretero, J.3
Altabef, A.4
Tchaicha, J.H.5
Christensen, C.L.6
-
42
-
-
0038491416
-
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor
-
Shin T, Kennedy G, Gorski K, Tsuchiya H, Koseki H, Azuma M, et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med. 2003;198:31-8.
-
(2003)
J Exp Med
, vol.198
, pp. 31-38
-
-
Shin, T.1
Kennedy, G.2
Gorski, K.3
Tsuchiya, H.4
Koseki, H.5
Azuma, M.6
-
43
-
-
0037867039
-
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism
-
Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003;197:1721-30.
-
(2003)
J Exp Med
, vol.197
, pp. 1721-1730
-
-
Liu, X.1
Gao, J.X.2
Wen, J.3
Yin, L.4
Li, O.5
Zuo, T.6
-
44
-
-
35548986304
-
Microglia: active sensor and versatile effector cells in the normal and pathologic brain
-
Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387-94.
-
(2007)
Nat Neurosci
, vol.10
, pp. 1387-1394
-
-
Hanisch, U.K.1
Kettenmann, H.2
-
45
-
-
77955534002
-
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
-
Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160-70.
-
(2010)
Cancer Cell
, vol.18
, pp. 160-170
-
-
Park, S.1
Jiang, Z.2
Mortenson, E.D.3
Deng, L.4
Radkevich-Brown, O.5
Yang, X.6
-
46
-
-
79955570584
-
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
-
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142-7.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 7142-7147
-
-
Stagg, J.1
Loi, S.2
Divisekera, U.3
Ngiow, S.F.4
Duret, H.5
Yagita, H.6
-
47
-
-
78650880204
-
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
-
Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010;12:R46.
-
(2010)
Breast Cancer Res
, vol.12
, pp. R46
-
-
Silva, L.1
Simpson, P.T.2
Smart, C.E.3
Cocciardi, S.4
Waddell, N.5
Lane, A.6
-
48
-
-
84940757399
-
Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases
-
Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, et al. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol. 2015;9:1241-9.
-
(2015)
Neuro Oncol
, vol.9
, pp. 1241-1249
-
-
Duchnowska, R.1
Sperinde, J.2
Chenna, A.3
Huang, W.4
Weidler, J.M.5
Winslow, J.6
-
49
-
-
84937961692
-
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
-
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75 Suppl 9:S1-09.
-
(2015)
Cancer Res
, vol.75
, pp. S1-09
-
-
Nanda, R.1
Chow, L.Q.2
Dees, E.C.3
Berger, R.4
Gupta, S.5
Geva, R.6
-
50
-
-
84965022830
-
Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
-
Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76 Suppl 4:S5-07.
-
(2016)
Cancer Res
, vol.76
, pp. S5-07
-
-
Rugo, H.S.1
Delord, J.-P.2
Im, S.-A.3
Ott, P.A.4
Piha-Paul, S.A.5
Bedard, P.L.6
-
51
-
-
84944041240
-
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastastic triple-negative breast cancer
-
Emens LA, Braiteh FS, Cassier PA, Delord J, Eder JP, Shen X, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastastic triple-negative breast cancer. Cancer Res. 2015;75 Suppl 9:PD1-6.
-
(2015)
Cancer Res
, vol.75
, pp. PD1-6
-
-
Emens, L.A.1
Braiteh, F.S.2
Cassier, P.A.3
Delord, J.4
Eder, J.P.5
Shen, X.6
-
52
-
-
85010223314
-
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
-
Dirix LY, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton EP, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76 Suppl 4:S1-04.
-
(2016)
Cancer Res
, vol.76
, pp. S1-04
-
-
Dirix, L.Y.1
Takacs, I.2
Nikolinakos, P.3
Jerusalem, G.4
Arkenau, H.-T.5
Hamilton, E.P.6
-
53
-
-
84902590227
-
Immune checkpoints: A therapeutic target in triple negative breast cancer
-
Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology. 2014;3:e28325.
-
(2014)
Oncoimmunology
, vol.3
, pp. e28325
-
-
Chawla, A.1
Philips, A.V.2
Alatrash, G.3
Mittendorf, E.4
|